Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 3

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 55Burkitt Lymphoma 27Neoplasm, Residual 13Leukemia 6Recurrence 5Leukemia, Biphenotypic, Acute 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Lymphoid 3Myelodysplastic Syndromes 2Lymphoma, B-Cell 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Hematologic Neoplasms 2Blast Crisis 2Sarcoma, Myeloid 1Philadelphia-Negative ALL 1Philadelphia Chromosome 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid 1Leukemia, Large Granular Lymphocytic 1Leukemia, B-Cell 1Hodgkin Disease 1Graft vs Host Disease 1

Interventions

fludarabine 6fludarabine phosphate 5Rituximab 5Cyclophosphamide 5Busulfan 4blinatumomab 3Lenalidomide 3thymoglobulin 2Whole-Body Irradiation 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Methotrexate 2Melphalan 2Bone Marrow Transplantation 2Biopsy 2Bendamustine Hydrochloride 2Behavior Therapy 2Alemtuzumab 2venetoclax 1sargramostim 1romiplostim 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1lirilumab 1ibrutinib 1duvelisib 1copanlisib 1Vincristine 1Thiotepa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Leukemia, Lymphoid × blinatumomab × Clear all
NCT06111625 2023-11-01

Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL

Sichuan University

Phase 2 Recruiting
20 enrolled
Other hematologic neoplasm

Leukemia, Lymphoid

NCT06075212 2023-10-10

Immune Reconstitution After Allo-HSCT and Blinatumomab

Sichuan University

Unknown
20 enrolled
Other hematologic neoplasm

Leukemia, Lymphoid

NCT06075238 2023-10-10

Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT

Sichuan University

Phase 2 Not yet recruiting
68 enrolled
Other hematologic neoplasm

Leukemia, Lymphoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡